TABLE 3.
HRs (95% CIs) for colorectal cancer incidence by E-DII quartile for all participants and stratified by sex and race/ethnicity, Multiethnic Cohort, 1993–20101
| Men |
Women |
|||||
| E-DII | Person-years (cases)2 | Minimally adjustedHR (95%CI)3 | Fully adjustedHR (95%CI)4 | Person-years (cases)2 | Minimally adjustedHR (95%CI)3 | Fully adjustedHR (95%CI)4 |
| White | ||||||
| Quartile 1 (−6.64 to −3.66) | 61,182 (77) | 1.00 (Ref) | 1.00 (Ref) | 120,341 (139) | 1.00 (Ref) | 1.00 (Ref) |
| Quartile 2 (−3.65 to −2.32) | 75,467 (119) | 1.32 (0.99, 1.75) | 1.29 (0.96, 1.71) | 112,518 (114) | 0.95 (0.74, 1.21) | 0.93 (0.72, 1.19) |
| Quartile 3 (−2.31 to −0.53) | 81,717 (100) | 1.08 (0.80, 1.45) | 0.99 (0.74, 1.34) | 84,222 (87) | 1.04 (0.79, 1.36) | 0.93 (0.71, 1.23) |
| Quartile 4 (−0.52 to 4.95) | 96,141 (155) | 1.62 (1.23, 2.13) | 1.39 (1.04, 1.84) | 65,835 (71) | 1.22 (0.92, 1.63) | 1.06 (0.78, 1.43) |
| Continuous | — | — | 1.05 (1.00, 1.10) | — | — | 1.02 (0.96, 1.07) |
| P-trend | — | — | 0.08 | — | — | 0.78 |
| African American | ||||||
| Quartile 1 (−6.64 to −3.66) | 26,000 (78) | 1.00 (Ref) | 1.00 (Ref) | 89,579 (188) | 1.00 (Ref) | 1.00 (Ref) |
| Quartile 2 (−3.65 to −2.32) | 34,197 (71) | 0.73 (0.53, 1.01) | 0.71 (0.52, 0.99) | 80,428 (142) | 0.90 (0.72, 1.12) | 0.93 (0.75, 1.17) |
| Quartile 3 (−2.31 to −0.53) | 43,109 (82) | 0.71 (0.52, 0.97) | 0.67 (0.49, 0.92) | 71,129 (97) | 0.77 (0.60, 0.98) | 0.82 (0.63, 1.05) |
| Quartile 4 (−0.52 to 4.95) | 54,607 (122) | 0.91 (0.68, 1.12) | 0.86 (0.63, 1.16) | 60,784 (115) | 1.21 (0.95, 1.53) | 1.24 (0.97, 1.60) |
| Continuous | — | — | 1.00 (0.95, 1.06) | — | — | 1.03 (0.98, 1.08) |
| P-trend | — | — | 0.70 | — | — | 0.20 |
| Japanese American | ||||||
| Quartile 1 (−6.64 to −3.66) | 65,180 (151) | 1.00 (Ref) | 1.00 (Ref) | 154,584 (267) | 1.00 (Ref) | 1.00 (Ref) |
| Quartile 2 (−3.65 to −2.32) | 66,789 (156) | 1.06 (0.85, 1.33) | 1.03 (0.82, 1.29) | 113,174 (184) | 1.01 (0.84, 1.22) | 0.98 (0.81, 1.82) |
| Quartile 3 (−2.31 to −0.53) | 93,320 (217) | 1.15 (0.94, 1.42) | 1.07 (0.87, 1.32) | 95,799 (116) | 0.85 (0.68, 1.05) | 0.81 (0.65, 1.01) |
| Quartile 4 (−0.52 to 4.95) | 139,893 (340) | 1.43 (1.17, 1.74) | 1.25 (1.02, 1.53) | 75,113 (102) | 1.12 (0.89, 1.42) | 0.94 (0.74, 1.21) |
| Continuous | — | — | 1.04 (1.01, 1.08) | — | — | 0.98 (0.94, 1.02) |
| P-trend | — | — | 0.01 | — | — | 0.28 |
| Latino | ||||||
| Quartile 1 (−6.64 to −3.66) | 47,793 (61) | 1.00 (Ref) | 1.00 (Ref) | 99,370 (89) | 1.00 (Ref) | 1.00 (Ref) |
| Quartile 2 (−3.65 to −2.32) | 74,656 (106) | 1.15 (0.84, 1.58) | 1.17 (0.85, 1.60) | 105,499 (106) | 1.16 (0.87, 1.53) | 1.16 (0.87, 1.54) |
| Quartile 3 (−2.31 to −0.53) | 97,796 (167) | 1.47 (1.10, 1.97) | 1.49 (1.10, 2.00) | 87,751 (87) | 1.20 (0.89, 1.61) | 1.14 (0.84, 1.54) |
| Quartile 4 (−0.52 to 4.95) | 82,994 (148) | 1.69 (1.25, 2.28) | 1.72 (1.26, 2.34) | 53,147 (54) | 1.32 (0.94, 1.85) | 1.21 (0.85, 1.71) |
| Continuous | — | — | 1.13 (1.07, 1.18) | — | — | 1.05 (0.98, 1.11) |
| P-trend | — | — | <0.01 | — | — | 0.32 |
| Native Hawaiian | ||||||
| Quartile 1 (−6.64 to −3.66) | 11,268 (14) | 1.00 (Ref) | 1.00 (Ref) | 29,989 (26) | 1.00 (Ref) | 1.00 (Ref) |
| Quartile 2 (−3.65 to −2.32) | 13,300 (24) | 1.51 (0.78, 2.93) | 1.43 (0.74, 2.78) | 26,421 (33) | 1.54 (0.92, 2.58) | 1.68 (0.99, 2.83) |
| Quartile 3 (−2.31 to −0.53) | 19,743 (47) | 2.11 (1.16, 2.93) | 1.95 (1.07, 3.56) | 26,345 (28) | 1.41 (0.82, 2.42) | 1.43 (0.82, 2.48) |
| Quartile 4 (−0.52 to 4.95) | 38,784 (62) | 1.58 (0.88, 2.85) | 1.29 (0.71, 2.35) | 30,669 (46) | 2.32 (1.42, 3.81) | 2.33 (1.38, 3.93) |
| Continuous | — | — | 1.00 (0.93, 1.08) | — | — | 1.14 (1.05, 1.24) |
| P-trend | — | — | 0.90 | — | — | <0.01 |
1
n = 190,963. E-DII, energy-adjusted Dietary Inflammatory Index; Ref, reference.
2
Person-year totals may not equal sex stratified totals because of rounding.
3
Age was included in the STRATA statement.
4
Self-reported previous diagnosis of diabetes, asthma, and heart attack; use of supplements; smoking status; family history of colon cancer; education; hormone (i.e., estrogen or progesterone) use; aspirin use; and BMI with age in the STRATA statement.